Zhejiang Haichang Biotech Co., Ltd.
Clinical trials sponsored by Zhejiang Haichang Biotech Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for liver cancer: drug combo targets tough cases Results expected Dec 2026 (estimated)
-
Experimental combo aims to tackle advanced liver cancer
Disease control Not yet recruitingThis study tests an experimental drug called WGI-0301 combined with lenvatinib in 80 people with advanced liver cancer who have already tried one treatment. The goal is to see if the combination is safe, tolerable, and shrinks tumors. It is an open-label, non-placebo trial across…
Phase 1/2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New combo therapy aims to shrink advanced liver and kidney tumors
Disease control Not yet recruitingThis study tests a new drug called WGI-0301 combined with the immunotherapy nivolumab in people with advanced liver or kidney cancer. The goal is to see if the combination is safe and can shrink tumors. About 230 adults aged 18 to 75 will take part, and the study does not use a p…
Phase 2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC